NASDAQ:HOTH - Hoth Therapeutics Stock Price, Forecast & News

Hoth Therapeutics trades on the NASDAQ under the ticker symbol "HOTH."

Hoth Therapeutics Inc (NASDAQ:HOTH) released its earnings results on Tuesday, November, 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.07. View Hoth Therapeutics' Earnings History.

Hoth Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Hoth Therapeutics.

2 brokers have issued 12-month price targets for Hoth Therapeutics' shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Hoth Therapeutics' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 105.8% from the stock's current price. View Analyst Price Targets for Hoth Therapeutics.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hoth Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hoth Therapeutics.

Press coverage about HOTH stock has trended somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hoth Therapeutics earned a media sentiment score of -1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Hoth Therapeutics.

Hoth Therapeutics saw a drop in short interest during the month of January. As of January 15th, there was short interest totalling 38,300 shares, a drop of 11.3% from the December 31st total of 43,200 shares. Based on an average daily volume of 26,400 shares, the short-interest ratio is presently 1.5 days. Approximately 0.9% of the shares of the company are sold short. View Hoth Therapeutics' Current Options Chain.

Some companies that are related to Hoth Therapeutics include Aptinyx (APTX), Obseva (OBSV), Chiasma (CHMA), Evelo Biosciences (EVLO), Nature's Sunshine Products (NATR), Bicycle Therapeutics (BCYC), Fortress Biotech (FBIO), Tyme Technologies (TYME), Spero Therapeutics (SPRO), IDEAYA Biosciences (IDYA), Arbutus Biopharma (ABUS), Harrow Health (HROW), Arcturus Therapeutics (ARCT), Monopar Therapeutics (MNPR) and Ovid Therapeutics (OVID).

Based on aggregate information from My MarketBeat watchlists, some companies that other Hoth Therapeutics investors own include Verizon Communications (VZ), General Motors (GM), NovaBay Pharmaceuticals (NBY), Cronos Group (CRON), Huntington Bancshares (HBAN), Inovio Pharmaceuticals (INO), Inseego (INSG), Novavax (NVAX), Sesen Bio (SESN) and Chesapeake Energy (CHK).

(HOTH) raised $8 million in an IPO on Friday, February 15th 2019. The company issued 1,300,000 shares at $5.50-$6.50 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

Shares of HOTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HOTH stock can currently be purchased for approximately $4.86.

Hoth Therapeutics has a market capitalization of $49.18 million. The company earns $-2,500,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Hoth Therapeutics employs 2 workers across the globe.View Additional Information About Hoth Therapeutics.

The official website for Hoth Therapeutics is http://www.hoththerapeutics.com/.

Hoth Therapeutics' mailing address is 1 Rockefeller Plaza Suite 1039, New York NY, 10020. The company can be reached via phone at 646-756-2997 or via email at [email protected]